Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Hyperglycemia
NCT ID: NCT03258229
Last Updated: 2019-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2017-02-09
2017-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia
NCT03775733
Efficacy and Safety of Hydrolyzed Ginseng Extract on Impaired Fasting Glucose
NCT01854164
Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients
NCT00786500
Hypoglycemic Efficacy of Greenyn Momordica Charantia Extracts in Diabetic Subjects
NCT03151837
Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients
NCT00808860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Angelica gigas N. extract
capsules(2cap/d, 1,000mg/d) for 8 weeks.
Angelica gigas N. extract
capsules(2cap/d, 1,000mg/d) for 8 weeks.
Placebo
Placebo for 8 weeks
Placebo
Placebo for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Angelica gigas N. extract
capsules(2cap/d, 1,000mg/d) for 8 weeks.
Placebo
Placebo for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hypoglycemic agent, Obesity medicine, Lipid lowering agent within past 6 months or Blood sugar, Obesity and Lipid improvement functional foods within past 2 weeks
* Treated with corticosteroid within past 4 weeks
* Severe cardiovascular disease(Mvocardial infarction, Stroke, etc)
* Renal disease(Heredity hyperlipidemia, Acute/Chronic renal failure, Nephrotic syndrome, etc)
* Rheumatoid arthritis, Autoimmune disease
* Cancer, Respiratory organ disease(Asthma, Chronic obstructive pulmonary disease)
* Allergic or hypersensitive to any of the ingredients in the test products
* History of disease that could interfere with the test products or impede their absorption
* Under antipsychotic drugs therapy within past 2 months
* History of alcohol or substance abuse
* Participation in any other clinical trials within past 2 months
* Laboratory test by show the following results
* aspartate aminotransferase, alanine aminotransferase \> Reference range upper limit treble
* Serum Creatinine \> 2.0 mg/dl
* Pregnancy or breast feeding
* Not Contraception(except: Surgery for female infertility)
20 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Soo-Wan Chae
Principal Investigator, Clinical Trial Center for Functional Foods
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WBP-HG-AG2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.